BiotechTube
Home/NewAmsterdam Pharma/Professor Dr. John Kastelein
PD

Professor Dr. John Kastelein

Co-founder and Chief Scientific Officer

NewAmsterdam Pharma

Therapeutic Areas

Cardiovascular DiseaseDyslipidemiaAlzheimer's Disease

NewAmsterdam Pharma Pipeline

DrugIndicationPhase
Obicetrapib MonotherapyHeterozygous Familial Hypercholesterolemia (HeFH)Phase 3
Obicetrapib + Ezetimibe (FDC)HeFH and/or ASCVDPhase 3
ObicetrapibCardiovascular OutcomesPhase 3

Leadership Team at NewAmsterdam Pharma

DM
Dr. Michael Davidson
Co-founding Chief Executive Officer
BJ
B.J. Jones
Chief Commercial Officer
View full NewAmsterdam Pharma profile